- Home
- MCRB vs PRPO Comparison
MCRB vs PRPO Comparison
Compare MCRB & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRB | PRPO |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2M | 42.0M |
| IPO Year | 2015 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MCRB | PRPO |
|---|---|---|
| Price | $2.53 | $22.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 72.7K | 69.3K |
| Earning Date | 11-04-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | N/A | ★ N/A |
| Revenue | $789,000.00 | ★ $24,049,000.00 |
| Revenue This Year | N/A | $233.72 |
| Revenue Next Year | N/A | $22.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $2.42 | $16.40 |
| 52 Week High | $29.98 | $33.63 |
Technical Indicators
Market Signals| Indicator | MCRB | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 21.14 | 36.20 |
| Support Level | N/A | $21.93 |
| Resistance Level | $9.53 | $24.78 |
| Average True Range (ATR) | 0.24 | 1.06 |
| MACD | -0.04 | -0.12 |
| Stochastic Oscillator | 7.70 | 20.98 |
Price Performance
Historical ComparisonAbout MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
About PRPO Precipio Inc.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.